Literature DB >> 27632052

Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.

Nicole J Gormley1, Ann T Farrell1, Richard Pazdur1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 27632052     DOI： 10.1001/jamaoncol.2016.3112

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  9 in total

1.  Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.

Authors:  Arvind Dasari; Axel Grothey; Scott Kopetz
Journal:  J Clin Oncol       Date:  2018-10-30       Impact factor: 44.544

Review 2.  Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Authors:  Even H Rustad; Eileen M Boyle
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

3.  An Analysis of Recent FDA Oncology Scientific Publications.

Authors:  Julie A Schneider; Andrew C Miklos; James Onken; Yutao Gong; Anna Maria Calcagno; Gideon M Blumenthal; Richard Aragon; Richard Pazdur
Journal:  Oncologist       Date:  2019-11-26

4.  Should minimal residual disease negativity be the end point of myeloma therapy?

Authors:  Kenneth C Anderson
Journal:  Blood Adv       Date:  2017-03-14

5.  An Analysis of Recent FDA Oncology Scientific Publications.

Authors:  Julie A Schneider; Andrew C Miklos; James Onken; Yutao Gong; Anna Maria Calcagno; Gideon M Blumenthal; Richard Aragon; Richard Pazdur
Journal:  Oncologist       Date:  2019-11-26

6.  Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Authors:  P Arana; B Paiva; M-T Cedena; N Puig; L Cordon; M-B Vidriales; N C Gutierrez; F Chiodi; L Burgos; L-L Anglada; J Martinez-Lopez; M-T Hernandez; A-I Teruel; M Gironella; M-A Echeveste; L Rosiñol; R Martinez; A Oriol; J De la Rubia; A Orfao; J Blade; J-J Lahuerta; M-V Mateos; J-F San Miguel
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

7.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

8.  The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.

Authors:  Julie A Schneider; Yutao Gong; Kirsten B Goldberg; Paul G Kluetz; Marc R Theoret; Laleh Amiri-Kordestani; Julia A Beaver; Lola Fashoyin-Aje; Nicole J Gormley; Adnan A Jaigirdar; Steven J Lemery; Pallavi S Mishra-Kalyani; Gregory H Reaman; Donna R Rivera; Wendy S Rubinstein; Harpreet Singh; Rajeshwari Sridhara; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

9.  Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.

Authors:  Hervé Avet-Loiseau; Jesus San-Miguel; Tineke Casneuf; Shinsuke Iida; Sagar Lonial; Saad Z Usmani; Andrew Spencer; Philippe Moreau; Torben Plesner; Katja Weisel; Jon Ukropec; Christopher Chiu; Sonali Trivedi; Himal Amin; Maria Krevvata; Priya Ramaswami; Xiang Qin; Mia Qi; Steven Sun; Ming Qi; Rachel Kobos; Nizar J Bahlis
Journal:  J Clin Oncol       Date:  2021-01-29       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.